Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell therapies, will release its second quarter 2025 financial results on August 4, 2025 after U.S. market close.
The company will host an investor conference call and webcast on August 5, 2025 at 8:00 AM ET / 2:00 PM CET to discuss Q2 results and provide business updates. Investors can access the call through domestic (+1-800-343-5172) or international (+1-203-518-9856) dial-in numbers using Conference ID: CLLSQ2.
Cellectis (NASDAQ: CLLS), una società biotecnologica in fase clinica specializzata in terapie geniche e cellulari, pubblicherà i suoi risultati finanziari del secondo trimestre 2025 il 4 agosto 2025 dopo la chiusura del mercato statunitense.
La società terrà una conference call e una webcast per gli investitori il 5 agosto 2025 alle 8:00 AM ET / 14:00 CET per discutere i risultati del secondo trimestre e fornire aggiornamenti sull’attività. Gli investitori potranno accedere alla chiamata tramite i numeri nazionali (+1-800-343-5172) o internazionali (+1-203-518-9856) utilizzando il codice conferenza: CLLSQ2.
Cellectis (NASDAQ: CLLS), una empresa biotecnológica en etapa clínica enfocada en terapias génicas y celulares, publicará sus resultados financieros del segundo trimestre de 2025 el 4 de agosto de 2025 después del cierre del mercado estadounidense.
La compañía realizará una conferencia telefónica y webcast para inversores el 5 de agosto de 2025 a las 8:00 AM ET / 2:00 PM CET para discutir los resultados del segundo trimestre y proporcionar actualizaciones comerciales. Los inversores podrán acceder a la llamada mediante los números nacionales (+1-800-343-5172) o internacionales (+1-203-518-9856) utilizando el ID de conferencia: CLLSQ2.
Cellectis (NASDAQ: CLLS)는 유전자 편집 및 세포 치료에 중점을 둔 임상 단계 생명공학 회사로, 2025년 2분기 재무 실적을 2025년 8월 4일 미국 시장 마감 후 발표할 예정입니다.
회사는 2025년 8월 5일 오전 8시 ET / 오후 2시 CET에 투자자 컨퍼런스 콜 및 웹캐스트를 개최하여 2분기 실적과 사업 업데이트를 논의할 예정입니다. 투자자들은 국내 전화번호 (+1-800-343-5172) 또는 국제 전화번호 (+1-203-518-9856)를 통해 컨퍼런스 ID: CLLSQ2를 사용하여 통화에 접속할 수 있습니다.
Cellectis (NASDAQ : CLLS), une société biotechnologique en phase clinique spécialisée dans l’édition génétique et les thérapies cellulaires, publiera ses résultats financiers du deuxième trimestre 2025 le 4 août 2025 après la clôture du marché américain.
La société organisera une conférence téléphonique et une webdiffusion pour les investisseurs le 5 août 2025 à 8h00 ET / 14h00 CET afin de discuter des résultats du deuxième trimestre et de fournir des mises à jour sur ses activités. Les investisseurs pourront accéder à l’appel via les numéros nationaux (+1-800-343-5172) ou internationaux (+1-203-518-9856) en utilisant l’ID de conférence : CLLSQ2.
Cellectis (NASDAQ: CLLS), ein biotechnologisches Unternehmen in der klinischen Phase mit Fokus auf Gen-Editing und Zelltherapien, wird seine Finanzergebnisse für das zweite Quartal 2025 am 4. August 2025 nach Börsenschluss in den USA veröffentlichen.
Das Unternehmen wird am 5. August 2025 um 8:00 Uhr ET / 14:00 Uhr CET eine Telefonkonferenz und Webcast für Investoren abhalten, um die Ergebnisse des zweiten Quartals zu besprechen und Geschäftsupdates zu geben. Investoren können über die nationalen (+1-800-343-5172) oder internationalen (+1-203-518-9856) Einwahlnummern mit der Konferenz-ID: CLLSQ2 an dem Anruf teilnehmen.
- None.
- None.
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2025 ending June 30, 2025 on Monday August 4, 2025 after the close of the US market.
The publication will be followed by an investor conference call and webcast on Tuesday August 5, 2025 at 8:00 AM ET / 2:00 PM CET. The call will include the Company’s second quarter results and an update on business activities.
Details for the call are as follows:
Dial in information:
Domestic: +1-800-343-5172
International: +1-203-518-9856
Conference ID: CLLSQ2
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1727030&tp_key=10a62ee950
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.
TALEN® is a registered trademark owned by Cellectis.
For further information on Cellectis, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93
Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com
Attachment
FAQ
When will Cellectis (CLLS) report Q2 2025 earnings?
How can investors join Cellectis Q2 2025 earnings call?
What is Cellectis (CLLS) main business focus?
What time is the Cellectis Q2 2025 earnings call in European time?
